We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients who received tandem autologous followed by allogeneic PSCT (auto-allo) with the outcomes of patients who underwent a reduced intensity conditioning allograft (early RIC) without prior autologous transplant. From 1996 to 2013, we identified a total of 690 patients: 517 patients were planned to receive auto-allo and 173 received an early RIC allograft without prior autologous transplant. With a median follow-up of 93 months, 5-year PFS survival was significantly better in the auto-allo group, 34% compared with 22% in the early RIC group (P o0.001). OS was also significantly improved in the auto-allo group with a 5-year rate of 59% vs 42% in the early RIC group (P = 0.001). The non-relapse mortality rate was lower in the auto-allo group than in the early RIC group, with 1-and 3-year rates of 8% and 13% vs 20% and 28%, respectively (P o 0.001). The relapse/progression rate was similar in the two groups, with 5-year rates of 50% for auto-allo and 46% for early RIC (P = 0.42). These data suggest that planned tandem autologous allograft can improve overall survival compared with upfront RIC allograft alone in patients with multiple myeloma.
INTRODUCTION
Despite the use of new targeted therapies for induction, consolidation and maintenance therapy in combination with autologous peripheral SCT (auto-PSCT), multiple myeloma remains largely incurable. Reduced intensity conditioning (RIC) allograft directly following auto-PSCT (tandem auto-allo) was developed as a means of improving disease control via the graft-vs-myeloma effect. Initial prospective studies reported low relapse and mortality rates for the auto-allo approach. 1, 2 These data led to several prospective randomized studies comparing tandem autoallo transplant to single or tandem auto-PSCT. [3] [4] [5] [6] [7] [8] [9] [10] Overall, studies show a lower relapse rate in allograft-containing arms but with no OS benefit. Two of the studies with long-term follow-up show improved PFS and OS in favor of tandem auto-allograft. 6, 10 Not surprisingly, the treatment-related mortality rates are higher with auto-allograft. With the combination of new targeted agents and auto-PSCT, delivering excellent disease response with limited toxicity, allogeneic peripheral SCT (allo-PSCT) has become a far less attractive option. Studies are ongoing to better define the most appropriate candidates for allograft in the setting of modern myeloma therapy. Currently, studies of reduced intensity allograft in high-risk patients proceed directly to allograft using new conditioning regimens and post-allograft maintenance therapy, without utilizing auto-PSCT. To address the role of auto-PSCT prior to RIC allograft, we conducted a retrospective analysis of patients with multiple myeloma who received upfront auto-allograft and compared outcomes with patients who received RIC allograft as their first transplant without prior auto-PSCT.
MATERIALS AND METHODS
This study was conducted on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation (EBMT). The EBMT represents 4500 transplantation centers in and beyond Europe, which report minimum essential data on all transplants into a central database. Informed consents were obtained locally according to the regulations applicable at the time of transplantation, with confirmation required by EBMT since January 2013.
Definitions
The diagnosis of multiple myeloma was based on local review. The planned auto-PSCT followed by allograft (auto-allo) as upfront transplant was documented at the time of registration. Auto-allo patients were included in this analysis even if they did not receive their planned allograft. The early RIC allograft group received RIC allograft as first transplant 1 without prior auto-PSCT. RIC was defined by EBMT as melphalan dose of ⩽ 140 mg/m 2 , busulfan dose of ⩽ 8 mg/kg, CY dose of o120 mg/kg and TBI dose o 600 cGy or 600 cGy if fractionated. 11 Cord blood was excluded as an allogeneic graft source. T-cell depletion was defined as use of ex vivo graft manipulation and or use of T-cell-depleting antibodies. Response and relapse/progression were defined using EBMT criteria. 12 
Study design
This study was a retrospective analysis of the EBMT database between the years 1996 and 2013 for all multiple myeloma patients registered as receiving either early RIC allograft as their first transplant or a planned auto-allo (whether or not they completed the planned allograft). The primary objectives of the study were to compare PFS, non-relapse mortality (NRM), relapse/progression and OS between the planned tandem auto-allo and early RIC allograft groups. Secondary objectives were to examine the engraftment rate and incidence of acute and chronic GVHD.
Statistical analyses
OS was assessed from the date of first transplant to death. PFS was assessed from the date of the first transplant until progression, relapse or death, whichever occurred first. Censoring was applied at last available follow-up to patients alive with no prior relapse/progression (for PFS) and to patients alive at the date of last contact (for OS). Relapse/progression and NRM (including non-progression mortality) cumulative incidence was calculated considering the two events as competing risks. The Log-Rank test was used to assess differences in univariate analysis for PFS and OS, and the Gray test was used for relapse/progression and NRM. Multivariate analyses were performed by Cox regression for OS and PFS and by the Fine and Gray model for relapse/progression and NRM. The variables considered in the model-building procedures were as follows: disease stage by Durie-Salmon (stage II-III vs I), disease status at transplant (CR/PR vs others), treatment group (early RIC vs auto-allo), calendar year, patient gender, age at transplant, and time interval from diagnosis to transplant. As the study followed an intent-to-treat approach, characteristics defined at allograft (thus not defined or unknown at the time of autologous transplant for the auto-allo group) were not included in the analyses. Because of a high percentage of missing data and evidence of informative missing values, β 2 -microglobin and cytogenetic data were not included in the analysis. Percentages are based on total number of patients who received allogeneic transplant and had data available for this outcome.
b Percentages are based on total number of patients who had data available for this best response.
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RESULTS

Patient, disease and treatment characteristics
Patient characteristics are shown in Table 1 . Preliminary data from this analysis were reported at the 2013 American Society of Hematology meeting in New Orleans. 13 A total of 690 patients were identified between 1996 and 2013. Five hundred and seventeen were registered as planned auto-allo and 173 patients as early RIC allograft with no prior auto-PSCT. Four hundred and seventy-two patients in the auto-allo group received their planned allograft, with 38 patients receiving myeloablative conditioning and 45 not ultimately receiving an allograft; however, all 517 were included in the analysis. We included all patients on the auto-allo arm, whether or not they received the planned reduced intensity allograft using an intention-to-treat approach. The median follow-up for the whole group is 93.5 months and similar between the two groups, with 93.8 months for the auto-allo group and 86.5 months in the early RIC group. Because of missing data on the use of new proteasome inhibitors and immunomodulatory drugs as induction therapy and changes in supportive care in transplant, the 2004 calendar year was used as a surrogate marker for introduction of novel agents to clinical practice and Allo-SCT more recently. More patients in the early RIC group received transplants before 2004 than in the auto-allo group, 61% vs 51%, P = 0.039. The median age was 53 years in the auto-allo group and 51 (31-77) in the early RIC group, P = 0.1. There were more males (61%) in the auto-allo group compared with the early RIC group (51%), P = 0.044. Disease stage at diagnosis by Durie-Salmon classification was 13% stage I, 20% stage II and 67% stage III in the autoallo group and 4% stage I, 22% stage II and 74% stage III in the early RIC group, P = 0.001. Time from diagnosis of multiple myeloma to first transplant was 6.6 months (2-156) in the autoallo and 7.7 months (2.8-12) in the early RIC group, P = 0.007. The cytogenetic data were available in only 245 patients (36%), with 227 patients in the auto-allo group. The β 2 microglobulin data at diagnosis were available in 309 patients (45%): 129 of the 279 patients (46%) in the auto-allo and 17 of the 30 patients (57%) in the early RIC group had β 2 microglobulin level ⩾ 3.5. There were more patients in CR (16%) at the time of transplant in the early RIC group than in the auto-allo group (9%) P = 0.048. Seventy-eight Reduced intensity allo-PSCT for multiple myeloma F Sahebi et al percent of patients in the auto-allo and 80% in the early RIC group had chemotherapy-sensitive (⩾ PR) disease at transplant.
Transplant characteristics
Transplant characteristics are shown in Table 2 . Donors were mostly matched related donors in both groups: 87% in the autoallo group, and 83% in the early RIC groups. Six percent of patients received matched unrelated donor grafts in the auto-allo group and 5% in the early RIC allograft group; mismatched related or unrelated donor grafts were 7% in the auto-allo group and 12% in the early RIC-allo group (P = 0.13). In the auto-allo group 26% received gender-mismatched transplants (female donor to male recipient) and 23% in the early RIC group, P = 0.5. In vivo or in vitro T-cell depletion using antithymocyte globulin, alemtuzumab (Campath) or ex vivo graft manipulation methods were utilized in 23% and 31% of the auto-allo and the early RIC groups, respectively, P = 0.052. The source of stem cells was peripheral blood in 94% of auto-allo and 87% of early RIC patients, and BM in 6% of auto-allo and 13% of early RIC patients. Conditioning regimens for auto-PSCT in the auto-allo group were mostly high-dose melphalan alone in 73% and other regimens in 27% of patients. A variety of different conditioning regimens was used prior to allograft in both groups: TBI-based (55%), Flu+Mel (23%) or a combination of Flu+other (6%) in the auto-allo group, and TBI-based (27%), Flu +Mel (34%) and Flu +other (28%) in the early RIC group.
Outcome data Outcome data are reported in Table 3 . Engraftment rates were similar between the two groups: 98% both in the auto-allo and in the early RIC group. Grade I acute GVHD occurred in 18%, grade II in 16%, grade III in 8% and grade IV in 3% (grade III-IV = 11%) of patients in the auto-allo group; and grade I in 15%, grade II in 15%, grade III in 7%, grade IV in 5% (grade III-IV = 12%) of patients in the early RIC group. Limited chronic GVHD occurred in 28% and 24% of patients, and extensive chronic GVHD occurred in 31% and 25% of patients in the auto-allo and early RIC groups, respectively.
Best responses reported after auto-allo included 323 (64%) CR and 163 (32%) PR, and in the early RIC group, 91 (60%) CR and 23 (15%) PR. Response data were missing in 11 and 20 patients in the auto-allo and the early RIC groups, respectively.
Three-and 5-year OS rates were 68% (64-72) and 59% (55-64) in the auto-allo group and 54% (46-62) and 42% (34-50) in the early RIC group, P o0.001, (Figure 1a ). Three-and 5-year PFS rates were 45% (41-50) and 34% (30-39) in the auto-allo group and 33% (25-41) and 22% (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) in the early RIC group, P o0.001 (Figure 1b) . The cumulative incidence of relapse at 3 and 5 years was 41% (37-45%) and 50% (46-55) in the auto-allo and 39% (31-46) and 46% (38-54) in the early RIC groups, respectively, P = 0.42 (Figure 1c) . The cumulative incidence of NRM at 1 and 3 years was 8% and 13% in the auto-allo and 20% and 28% in the early RIC group, P o 0.001 (Figure 1d ). Main causes of death are listed in Table 3 .
The results of multivariate analysis are shown in Table 4 . In the multivariate analysis of PFS, age at transplantation, advanced disease stages (II, III), disease status (not in CR/PR) and treatment groups (early RIC) were significantly associated with worse PFS. Multivariate analysis of OS showed that age at transplantation, treatment group (early RIC) and disease status (not in CR/PR) were associated with inferior OS. Age at transplantation, treatment group (early RIC) and time from diagnosis to transplant were associated with increased NRM in multivariate analyses. Only advanced stage was significantly associated with worse relapse/ progression by multivariate analysis.
Because of the potential impact of the introduction of novel agents into clinical practice over the years, absence of data on the use of these agents, and disparity in the calendar year of treatment between the two groups, we used 2004 as a surrogate year for the introduction of novel agents to clinical practice and advances in Allo-SCT and analyzed the impact of calendar year on outcome. There were no differences for any outcomes between the two groups before or after 2004, indicating that calendar year and, presumably, the introduction of novel agents did not contribute significantly to the better outcomes in the auto-allo group (Figure 2) .
DISCUSSION
Induction therapy with targeted agents followed by Auto-SCT is considered the standard-of-care for patients with multiple myeloma. RIC allograft is recommended in the setting of clinical trials in high-risk patients who are unlikely to have long-term disease control with standard auto-PSCT strategies.
14 Although studies are underway to investigate the role of new conditioning regimens and postallograft consolidation/maintenance therapy, the role of auto-PSCT prior to allograft remains unclear. In several ongoing studies, eligible patients undergo allo-PSCT directly after induction therapy without autologous transplant. This change of Abbreviations: CI = confidence interval; RIC = reduced intensity conditioning; s.e. = standard error.
Reduced intensity allo-PSCT for multiple myeloma F Sahebi et al strategy has occurred without any data on the potential role of auto-PSCT prior to allograft. To address this question, we conducted a retrospective analysis to define the influence of auto-PSCT prior to allograft in long-term outcomes. To our knowledge, this is the largest study comparing tandem autoallografts to upfront RIC allograft without any previous auto-PSCT. In the present study, patients undergoing auto-allograft had better PFS (3-and 5-year 45% and 34%) and OS (3-and 5-year 68% and 59%) than patients receiving early RIC alone. This was mainly due to lower NRM (3-year NRM of 13% for auto-allo vs 28% for RIC). Although non-relapse causes of death (Table 3) are similar between the two groups, the NRM curves separate significantly as a result of more early mortality events in the RIC group compared with the auto-allo group (Figure 1d ). There are several potential explanations for higher NRM in the early RIC group. It is possible that high-risk disease was the reason patients were selected for upfront RIC allograft, which could account for the higher NRM. In an attempt to address this issue, we sent surveys to the EBMT centers asking specific questions regarding the reasons for the type of transplant chosen and more information on adverse prognostics factors. We obtained responses on 175 (145 auto-allo and 30 RIC) of the 690 total patients. The primary reason for the type of transplant chosen was clinical protocols at the participating institutions (62% auto-allo and 24% early RIC patients). Unfortunately, no additional data on prognostic factors were reported. Therefore, the potential contribution of disease-related biology or patient comorbidities to this higher NRM cannot be excluded. Another potential explanation for the higher NRM in the early RIC group is a trend toward greater use of T-cell depletion in the early RIC compared with the auto-allo group (31% vs 23% P = 0.052). A report by Crawley et al. 15 showed that T-cell depletion using alemtuzumab was associated with inferior outcomes after RIC allograft. An additional possible explanation of the higher NRM in the early RIC group is differing intensity of the allograft conditioning regimens between the two groups. Although the intensity of allograft conditioning regimens was heterogeneous in both groups, we cannot exclude the possibility that patients in the early RIC group received higher intensity regimens. The distinctions between non-myeloablative and RIC between the two groups were impossible to determine as many of the transplants were performed before these terms were well defined. 16 We can also speculate that separation of high-dose cytoreductive chemotherapy from the allograft may make the regimen more tolerable resulting in lower NRM.
There are limited data reported on the use of upfront allograft RIC early in the course of multiple myeloma without preceding auto-PSCT. Our study that includes 173 early RIC patients is the largest study reported to date. Ringden et al. 17 investigated the effect of acute and chronic GVHD on relapse and survival for RIC allograft in multiple myeloma patients. Their study included a mixed population of 177 patients who received auto-allo and early RIC allograft without prior auto-PSCT. They reported significantly better EFS in the auto-allo group as compared with the RIC group with no prior auto-PSCT in patients who developed chronic GVHD. In our large registration study comparing auto-allo to RIC transplantation, in patients with multiple myeloma we observed better PFS and OS in favor of the auto-allograft group. It is also important to note that analysis of the auto-allo group Time was also analyzed in multi-variate analysis as a continuous variable, with no significant differences seen.
included patients who did not proceed with their planned allograft (intention to treat). The PFS and OS rates for the auto-allograft group in our study are very similar to those seen in previous prospective auto-allo studies with long-term follow-up, 5, 6, [18] [19] [20] strengthening our findings. It is unlikely that any study will be performed to address the role of auto-PSCT prior to allogeneic transplant in the future. Based on the large number of patients in our study with long-term follow-up of 93 months, a beneficial role of auto-PSCT prior to allograft should not be overlooked, and future allogeneic strategies should consider the use of auto-PSCT prior to allograft. Furthermore, the advantage of reduced NRM with the autoallograft approach cannot be dismissed even though the relapse incidence is similar to early RIC. For multiple myeloma, relapse following allogeneic transplant may not necessarily reflect a complete failure or carry the same weight as NRM. Survival after allograft appears to be durable based on long-term follow-up 21, 22 allowing an opportunity to use emerging therapeutic strategies as they become available.
